The Second China and Japan Joint Hypertension Symposium: Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: Role of bradykinin and nitric oxide

Hypertension Research

Volumn 23, Issue 3, 2000, Pages 253-259

  Kitakaze, Masafumi ^a   Node, Koichi ^a   Takashima, Seiji ^a   Minamino, Tetsuo ^a   Kuzuya, Tsunehiko ^a   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin; Bradykinin; Heart; Ischemia; Necrosis; NO; Stunning

Indexed keywords

BRADYKININ; CILAZAPRILAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; IMIDAPRILAT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; DOG; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; STUNNED HEART MUSCLE; ANIMAL; HEART MUSCLE; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL STUNNING; MYOCARDIUM; NITRIC OXIDE;

EID: 0034182085     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.23.253     Document Type: Conference Paper

References (41)

1. Victor JD, Richard EP: Renin-angiotensin system, in Fozzard HA (ed): The Heart and Cardiovascular System. New York, Raven Press, 1992, pp 1817-1849.
2. Drimal J: Effects of angiotensin II on coronary smooth muscle. Eur J Pharmacol 1968; 5: 56-62.
3. Erdos EG, Skdgel RA: The angiotensin-I converting enzyme. Lab Invest 1987; 56: 345-348.
4. Erdos EG: Angiotensin I converting enzyme and changes in our concepts through the years. Hypertension 1990; 16: 363-370.
5. Wolfgang L, Gabriele W, Bernward AS: ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 1992; 24: 909-919.
6. Schini VB, Boulanger C, Regoli D, Vanhoutte PM: Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 1990; 252: 581-585.
7. Kitakaze M, Minamino T, Node K, et al. Beneficial effects of inhibition of angiotensin converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 1995; 92: 950-961.
8. Kitakaze M, Node K, Minamino T, et al: Inhibition of angiotensin converting enzyme increases the nitric oxide levels in canine ischemic myocardium. J Mol Cell Cardiol 1998; 30: 2461-2466.
9. Arnold WP, Mittal CK, Katsuki S, Murad F: Nitric oxide activates guanylate cyclase and increased guanosine 3: 5′-cyclic monophosphate levels in various tissue preparation. Proc Natl Acad Sci USA 1977; 74: 3203-3207.
10. Pelc CS LR, Garrett JG, David CW: Mechanism of coronary vasodilation produced by bradykinin. Circulation 1991; 83: 2048-2056.
11. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1-46.
12. Janina SW, Owen LW: Kinin receptors mediating the effects of bradykinin on the coronary circulation in anesthetized greyhounds. Eur J Pharmacol 1991; 196: 9-14.
13. Creager MA, Halperin JL, Bernard DB, et al: Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation 1981; 64: 483-489.
14. Morales C, Rodriguez M, Scapin O, Gelpi R: Comparison of the effects of ACE inhibition with those of angiotensin II receptor antagonism on systolic and diastolic myocardial stunning in isolated rabbit heart. Mol Cell Biochem 1998; 186: 117-121.
15. Heusch G, Rose J, Ehring T: Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion: the importance of bradykinin. Drugs 1997; 54 (Suppl 5): 31-41.
16. Heusch G, Schulz R: Characterization of hibernating and stunned myocardium. Eur Heart J 1997; 18 (Suppl D): D102-D110.
17. Rose J, Ehring T, Sakka SG, Skyschally A, Heusch GJ: Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat. Mol Cell Cardiol 1996; 28: 603-613.
18. Schulz R, Heusch G: Characterization of hibernating and stunned myocardium. Eur Heart J 1995; 16 (Suppl J): 19-25.
19. Ehring T, Baumgart D, Krajcar M, Hummelgen M, Kompa S, Heusch G: Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation 1994; 90: 1368-1385.
20. Kitakaze M, Hori M: It is time to ask what adenosine can do for cardioprotection (Brief Review). Heart Vessels 1998; 13: 211-228.
21. ω-Nitro-L-arginine methyl ester in the cat. Circ Res 1992; 70: 364-369.
22. Yao SK, Akhtar S, Burden TS, et al: Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Circulation 1995; 92; 1005-1010.
23. Node K, Kitakaze M, Kosaka H, et al: Increased release of NO during ischemia decreases myocardial contractility and improves metabolic dysfunction. Circulation 1996; 93: 356-364.
24. Sakuma I, Togashi H, Yasuda H, Gross S, Levi R: NG-Methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo: a role for nitric oxide in the central regulation of sympathetic tone? Circ Res 1992; 70: 607-611.
25. Ma XL, Weyrich AS, Lefer DJ, Lefer AM: Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993; 72: 403-412.
26. Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA: Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996; 27: 7-13.
27. Wiemer G, Sholkens BA, Becker RHA, Busse R: Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived relaxant factor. Hypertension 1991; 18: 558-563.
28. Linz W, Wiemer G, Scholkens BA: ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 1992; 24: 909-919.
29. Cowan CL, Cohen RA: Two mechanisms mediate the relaxation by bradykinin of pig coronary artery: NO-dependent and -independent responses. Am J Physiol 1991: 261: H830-H835.
30. Nagao T, Vanfoutte PM: Hyperpolarization as a mechanism for endothelium-dependent relaxation in the porcine coronary artery. J Physiol (Lond) 1992; 445: 355-367.
31. + channels in the protective effect of ACE inhibition against ischemic myocardial injury. Hypertension 1998; 31: 1290-1298.
32. Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J: Antineutrophil and myocardial protecting action of a novel nitric oxide donor after acute myocardial ischemia and reperfusion in dogs. Circulation 1993; 88: 2337-2350.
33. 2+ current: involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 1993; 268: 26286-26295.
34. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T: Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 1993; 90: 347-351.
35. Depre C, Vanoverschelde JL, Goudemant JF, Mottet R, Hue L: Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation 1995; 92: 1911-1918.
36. Naseem SA, Kontos MC, Rao PS, Jesse RL, Hess ML, Kukreja RC: Sustained inhibition of nitric oxide by NG-nitro-L-arginine improves myocardial function following ischemia/reperfusion in isolated perfused rat heart. J Mol Cell Cardiol 1995; 27: 419-426.
37. Shulz R, Wambolt R: Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. Cardiovasc Res 1995; 30: 432-439.
38. Cole WC, McPherson CD, Sontag D: ATP-regulated channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991; 69: 571-581.
39. Linz W, Martorana PA, Scholkens BA: Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990; 15: (Suppl) S99-S109.
40. Martorana PA, Kettenbach B, Breipohl G, Linz W, Scholkens BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990; 182: 395-396.
41. Christina B, Mark AM: Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother 1993; 27: 755-766.